Although the management of lung cancer has improved over time with increasing survival rates, medical oncologists are regularly faced with the challenge of incorporating new immunotherapeutic and targeted treatment options in the management of patients with advanced NSCLC. Medical oncologists should be aware of the latest clinical data with cemiplimab identified in the multicenter, open-label EMPOWER-Lung 1 phase 3 study, which evaluated first-line therapy with cemiplimab in the advanced NSCLC setting among patients, regardless of PD-L1 expression. Significant improvements in terms of both progression-free survival and overall survival were observed. As prior studies, such as KEYNOTE-042 and CheckMate-227, did not conclusively show a survival benefit in patients with PD-L1 expression <50%, these results for the first time show an unequivocal treatment benefit across all patients with NSCLC, regardless of PD-L1 expression.
Differentiating the newest therapies from earlier treatments, such as pembrolizumab, nivolumab, durvalumab, and atezolizumab, remains an important challenge in medical oncologists. It is important for clinicians to offer the most up-to-date treatment regimens to their patients with newly diagnosed advanced NSCLC. By integrating these data, oncologists are able to reduce uncertainty and improve their confidence in the use of therapeutic strategies that have unequivocal benefit, regardless of initial tumor proportion scores.
About Med Learning Group
Med Learning Group, a division of Ultimate Medical Academy, is a full-service, accredited medical education company. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for both the patient and the practitioner.
Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive, and patient-centric in nature. We apply adult learning theory and principles to our programs and, more importantly, understand the nuances of our specialty audiences. We design programs for physicians, nurses, pharmacists, and other healthcare practitioners and have a deep understanding of how to educate both specialty audiences and general practitioners. The mission of Med Learning Group is to design educational activities for healthcare practitioners that increase competence, change behavior, and optimize patient care. The major focus of our education is the creation of innovative and interactive educational programs designed with scientific rigor, fair balance, and evidence-based content.